Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2002 5
2003 4
2004 1
2005 1
2006 1
2007 7
2008 9
2009 10
2010 6
2011 10
2012 15
2013 7
2014 9
2015 6
2016 8
2017 4
2018 3
2019 2
2020 2
2021 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 22135078

98 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of relapsed acute myeloid leukemia with MLL/AF6 fusion after allogeneic hematopoietic stem cell transplantation with gemtuzumab ozogamicin with a long interval followed by donor lymphocyte infusion.
Tamai H, Shioi Y, Yamaguchi H, Okabe M, Wakita S, Mizuki T, Nakayama K, Inokuchi K, Tajika K, Dan K. Tamai H, et al. Leukemia. 2008 Jun;22(6):1273-4. doi: 10.1038/sj.leu.2405029. Epub 2007 Nov 8. Leukemia. 2008. PMID: 17989711 No abstract available.
Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.
Roman E, Cooney E, Harrison L, Militano O, Wolownik K, Hawks R, Foley S, Satwani P, Unal E, Bhatia M, Bradley B, Del Toro G, George D, Garvin J, van de Ven C, Cairo MS. Roman E, et al. Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7164s-7170s. doi: 10.1158/1078-0432.CCR-1004-0018. Clin Cancer Res. 2005. PMID: 16203817 Clinical Trial.
A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S, Bhatia M, Ricci A, Roy S, Morris E, Harrison L, van de Ven C, Fabricatore S, Wolownik K, Cooney-Qualter E, Baxter-Lowe LA, Luisi P, Militano O, Kletzel M, Cairo MS. Zahler S, et al. Biol Blood Marrow Transplant. 2016 Apr;22(4):698-704. doi: 10.1016/j.bbmt.2016.01.019. Epub 2016 Jan 16. Biol Blood Marrow Transplant. 2016. PMID: 26785332 Free article. Clinical Trial.
Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin.
Fernandez HF, Sun Z, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald G, Ketterling RP, Rowe JM, Lazarus HM, Tallman MS. Fernandez HF, et al. Blood. 2011 May 19;117(20):5306-13. doi: 10.1182/blood-2010-09-309229. Epub 2011 Mar 17. Blood. 2011. PMID: 21415269 Free PMC article. Clinical Trial.
98 results